[PDF] Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma

Source:
Canadian Urological Association
Publisher:
Canadian Urological Association
Publication date:
01 July 2018

Abstract

Renal cell carcinoma (RCC) accounts for approximately 3% of all malignancies. RCC is about twice as common in males. It is the seventh most common cancer and 11th most common cause of cancer-related deaths among men., Cigarette smoking, obesity, and hypertension are the most well-established risk factors for sporadic RCC. Acquired cystic kidney disease (ACKD) is also a significant risk factor. Other studies have linked occupational exposure to RCC. As many as 5% of patients with RCCs are associated with germline mutations. There are a number of different hereditary diseases that are associated with RCC, including von Hippel-Lindau (VHL), hereditary papillary renal carcinoma (HPRC), Birt-Hogg-Dubé (BHD), hereditary leiomyomatosis renal cell carcinoma (HLRCC), succinate dehydrogenase kidney cancer (SDH-RCC), tuberous sclerosis complex (TSC), and Cowden’s disease. There are different options for management of patients with clinically localized renal masses suspicious for RCC, including active surveillance, ablation, and surgery.